29,348 Shares in ICU Medical, Inc. $ICUI Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 29,348 shares of ICU Medical during the second quarter, valued at approximately $4.3 million and representing a 0.12% stake. Institutional investors and hedge funds collectively own 96.1% of the company.
• Analyst sentiment remains positive, with ICU Medical holding a consensus “Moderate Buy” rating and an average price target of $192.80. Several firms recently raised their targets to $195–$200.
• ICU Medical exceeded quarterly expectations, reporting $2.37 in EPS versus the $1.91 consensus and revenue of $547.88 million. However, insiders sold 16,974 shares worth about $3.1 million over the past 90 days.

Deutsche Bank AG purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 29,348 shares of the medical instruments supplier's stock, valued at approximately $4,302,000. Deutsche Bank AG owned 0.12% of ICU Medical as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock valued at $387,313,000 after acquiring an additional 89,755 shares during the period. Janus Henderson Group PLC increased its stake in ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier's stock valued at $345,607,000 after purchasing an additional 99,256 shares in the last quarter. Millennium Management LLC raised its holdings in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after purchasing an additional 690,694 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of ICU Medical by 6.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock worth $127,053,000 after purchasing an additional 63,026 shares in the last quarter. Finally, State Street Corp grew its stake in shares of ICU Medical by 2.8% in the 4th quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier's stock valued at $134,491,000 after buying an additional 25,545 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

Analyst Ratings Changes

ICUI has been the topic of a number of research reports. Piper Sandler upped their price target on ICU Medical from $163.00 to $195.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Zacks Research lowered ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Raymond James Financial reiterated a "strong-buy" rating and issued a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. Wall Street Zen upgraded shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, BTIG Research upped their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.

ICU Medical Stock Down 0.2%

ICUI stock opened at $182.24 on Wednesday. The stock's 50 day moving average is $162.42 and its 200-day moving average is $143.53. ICU Medical, Inc. has a twelve month low of $112.50 and a twelve month high of $192.85. The firm has a market capitalization of $4.55 billion, a PE ratio of 154.44, a P/E/G ratio of 2.31 and a beta of 0.74. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The business had revenue of $547.88 million for the quarter, compared to analysts' expectations of $533.44 million. During the same period last year, the business earned $2.10 EPS. The business's revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts expect that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.

Insider Activity

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company's stock, valued at approximately $888,860.08. This represents a 7.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel Woolson sold 5,417 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the sale, the vice president owned 17,062 shares of the company's stock, valued at approximately $3,093,852.46. This trade represents a 24.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 16,974 shares of company stock valued at $3,085,844 over the last ninety days. Company insiders own 2.10% of the company's stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.